Verve Therapeutics (VERV) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50.70%. A quarter ago, it was expected that this biotechnology firm would post a loss of $0.72 per share when it actually produced a loss of $0.58, delivering a surprise of 19.44%.Over the last four quarters, the compan ...

分组1 - Kamada reported quarterly earnings of $0.07 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.04 per share a year ago [1] - The company posted revenues of $44.02 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 5.28%, compared to $37.74 million in the same quarter last year [2] - Kamada shares have increased approximately 13.1% since the beginning of the year, outperforming the S&P 500's gain of 0.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $44.55 million, and for the current fiscal year, it is $0.27 on revenues of $179.87 million [7] - The Medical - Biomedical and Genetics industry, to which Kamada belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8]

Kolibri Global Energy Inc. (KGEI) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.08%. A quarter ago, it was expected that this company would post earnings of $0.14 per share when it actually produced earnings of $0.16, delivering a surprise of 14.29%.Over the last four quarters, t ...

European Wax Center, Inc. (EWCZ) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 340%. A quarter ago, it was expected that this company would post earnings of $0.05 per share when it actually produced earnings of $0.16, delivering a surprise of 220%.Over the last four quarters, the co ...

Company Performance - M-tron Industries, Inc. reported quarterly earnings of $0.56 per share, missing the Zacks Consensus Estimate of $0.66 per share, but showing an increase from $0.53 per share a year ago, resulting in an earnings surprise of -15.15% [1] - The company posted revenues of $12.73 million for the quarter ended March 2025, which was 2.06% below the Zacks Consensus Estimate, but an increase from $11.19 million year-over-year [2] - Over the last four quarters, M-tron Industries has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - M-tron Industries shares have increased approximately 18.5% since the beginning of the year, contrasting with a -0.6% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.66 on revenues of $13.2 million, and for the current fiscal year, it is $2.72 on revenues of $53.7 million [7] Industry Outlook - The Engineering - R and D Services industry, to which M-tron Industries belongs, is currently ranked in the top 9% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact M-tron Industries' stock performance [5][6]

Actelis Networks, Inc. (ASNS) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced a loss of $0.26, delivering a surprise of -1,200%.Over the last four quarters, the company has sur ...

Financial Performance - Inovio Pharmaceuticals reported a quarterly loss of $0.51 per share, better than the Zacks Consensus Estimate of a loss of $0.74, and an improvement from a loss of $1.31 per share a year ago, representing an earnings surprise of 31.08% [1] - The company posted revenues of $0.07 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 30%, compared to zero revenues a year ago [2] Stock Performance - Inovio shares have increased by approximately 6% since the beginning of the year, while the S&P 500 has declined by 0.6% [3] - The current Zacks Rank for Inovio is 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.60 on revenues of $0.05 million, and for the current fiscal year, it is -$2.27 on revenues of $7.7 million [7] - The Medical - Biomedical and Genetics industry, to which Inovio belongs, is currently in the top 35% of Zacks industries, suggesting a favorable outlook for stocks within this sector [8]

分组1 - ClearPoint Neuro, Inc. reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.15, representing an earnings surprise of -46.67% [1] - The company posted revenues of $8.49 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 2.85%, and showing an increase from $7.64 million in the same quarter last year [2] - ClearPoint Neuro has surpassed consensus revenue estimates three times over the last four quarters, while it has only surpassed consensus EPS estimates once in the same period [2] 分组2 - The stock has underperformed the market, losing about 11.3% since the beginning of the year compared to the S&P 500's decline of -0.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.16 on revenues of $9.2 million, and for the current fiscal year, it is -$0.62 on revenues of $38.95 million [7] - The Medical - Instruments industry, to which ClearPoint Neuro belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Company Performance - Eton Pharmaceuticals reported quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share, compared to a loss of $0.03 per share a year ago, representing an earnings surprise of -22.22% [1] - The company posted revenues of $17.28 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.71%, and this is an increase from year-ago revenues of $7.97 million [2] - Over the last four quarters, Eton Pharmaceuticals has surpassed consensus revenue estimates three times [2] Stock Performance - Eton Pharmaceuticals shares have increased approximately 30.3% since the beginning of the year, while the S&P 500 has declined by -0.6% [3] - The current consensus EPS estimate for the coming quarter is $0.07 on revenues of $16.7 million, and for the current fiscal year, it is $0.53 on revenues of $75.35 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Eton Pharmaceuticals belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Company Performance - MacroGenics reported a quarterly loss of $0.65 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.61, and an improvement from a loss of $0.84 per share a year ago, indicating a surprise of -6.56% [1] - The company posted revenues of $13.19 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 5.45%, but showing an increase from $9.1 million in the same quarter last year [2] - Over the last four quarters, MacroGenics has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - MacroGenics shares have declined approximately 51.1% since the beginning of the year, contrasting with the S&P 500's decline of -0.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $18.13 million, and for the current fiscal year, it is -$2.21 on revenues of $78.51 million [7] Industry Outlook - The Medical - Products industry, to which MacroGenics belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The earnings outlook for MacroGenics is favorable, with a Zacks Rank of 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]